Revisiting Foam Sclerotherapy: Challenging the 7 mm Dogma
Haroun Gajraj, a Self-Employed Phlebologist, posted on LinkedIn.
”An excellent demonstration of the utility of Foam Sclerotherapy for Superficial Venous Disease.
Dogma (aka Guidelines) tells us that Foam is only useful for veins up to 7 mm.
Even then, long-term durability is widely thought to be inferior to endothermal ablation.
Thank you Massimo Pozza for sharing your expertise.
Those who get inferior results are not doing it right. Simple as that!”
Quoting Massimo Pozza‘s post:
” This is a very interesting case because the patient had a VGS dilation of about 2.4 cm at 30 cm from the crosse (average diameter calculated on the teaching of Dr. Sica of Paris) with this abnormal antero-medial collateral.
I treated the VGS with direct puncture to the middle lower III of the thigh with 1% R L/A 1/4 foam about 8cc and then I treated the coarse collateral with atxscl 0.5/0.7% foam at the control after about 6 years the patient does not have recanalization of either the VGS or the coarse collateral and I limited myself to the treatment of some small collateral legs.
This is to highlight the
The fact is that very often it is enough to use delicate concentrations to have excellent results and that I prefer to use more aggressive concentrations depending on the patient’s response, which is different from person to person.
I always use Nadiax 3 nanoemulsion cream before and after the treatment and in this case elastocontension 35 mmHg for 7 days.”
” 
Stay updated with Hemostasis Today.
-
Dec 19, 2025, 13:30PPTA Europe’s Holiday Message: Wishing Health, Rest, and Renewal for 2026
-
Dec 19, 2025, 13:22If You Were Reading a “Bible for Blood Donation Volunteers,” What’s the ONE Thing That Must Be in It?
-
Dec 19, 2025, 12:52Julia Owens: Stroke Remains One of the World’s Leading Causes of Death and Disability
-
Dec 19, 2025, 12:03Pradeep Natarajan: Our New Genetic Study of Aortic Stenosis in ~3M
-
Dec 19, 2025, 11:47ESO Blog: Anna Gardin on Stroke Risk in the Era of Climate Extremes
-
Dec 19, 2025, 10:51Sarah Elkourashy Presents Insights on Caplacizumab for TTP at ASH25
-
Dec 19, 2025, 10:08Camilla Lombardi Shares an EHC Nutrition Guide for People with Bleeding Disorders
-
Dec 19, 2025, 09:56Danny Hsu Shares The ”I-WISh” Study by Nichola Cooper on ITP
-
Dec 19, 2025, 09:39Paul Bolaji: A Landmark Achievement -The Historic 1st Nigerian Stroke Leaders’ Summit 2025